Kiniksa Pharmaceuticals International (KNSA) cash on hand

Cash · fiscal 2025
$414.07M

Kiniksa Pharmaceuticals International (KNSA) held cash of $414.07M at the end of fiscal 2025 (December 31, 2025). That is 70.0% higher than the $243.63M of fiscal 2024. Figures as of 18 Nov 2026, 04:58 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Cash, fiscal 2025
$414.07M
Change on fiscal 2024
+70.0%
Highest on record
$414.07Mfiscal 2025
Lowest on record
$190.61Mfiscal 2022
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Kiniksa Pharmaceuticals International cash on hand, in more detail

Across the 4 fiscal years on record (2022–2025), the highest was $414.07M in fiscal 2025 and the lowest $190.61M in fiscal 2022.

History · 4 fiscal years

Cash by fiscal year

Kiniksa Pharmaceuticals International cash on hand, year by year

Kiniksa Pharmaceuticals International (KNSA) cash on hand by fiscal year
Fiscal yearCashChangeYear ended
2025$414.07M 70.0% up
2024$243.63M 18.1% up
2023$206.37M 8.3% up
2022$190.61M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

How to read it

Cash is the cushion that pays for bad years, buybacks and acquisitions; compare it with total debt to see whether the company is a net borrower.

Cash at health care companies of similar size

Cash of Kiniksa Pharmaceuticals International and comparable companies
CompanyCashFiscal year
Alkermes ALKS$588.22M2025
PACS Group PACS$197.02M2025
Kiniksa Pharmaceuticals International KNSA$414.07M2025
ImmunityBio IBRX$242.82M2025
Cytokinetics CYTK$882.22M2025
ABIVAX ABVX€530.38M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on KNSA

Kiniksa Pharmaceuticals International, figure by figure

Kiniksa Pharmaceuticals International (KNSA) overview: price, valuation and scorecardAll health care companies by market value

Kiniksa Pharmaceuticals International cash on hand: questions and answers

How much cash does Kiniksa Pharmaceuticals International have?

Kiniksa Pharmaceuticals International (KNSA) held cash of $414.07M at the end of fiscal 2025 (December 31, 2025). That is 70.0% higher than the $243.63M of fiscal 2024.

What are the highest and lowest cash figures on record for Kiniksa Pharmaceuticals International?

Across the 4 fiscal years on record (2022–2025), the highest was $414.07M in fiscal 2025 and the lowest $190.61M in fiscal 2022.

How is Kiniksa Pharmaceuticals International's cash calculated?

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Kiniksa Pharmaceuticals International (KNSA) cash on hand”, data as of 18 November 2026. https://funkfolio.com/stock/KNSA/cash

Underlying data: the company's filings with the SEC and Yahoo Finance.